CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04242238
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:23.742711+00:00
Published At: 2025-08-28T00:00:00+00:00
Record Updated At: 2025-08-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Sarcoma", "Advanced Sarcoma", "High Grade Sarcoma", "Leiomyosarcoma", "Undifferentiated Pleomorphic Sarcoma", "Myxofibrosarcoma", "Dedifferentiated Liposarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-28"
protocolSection.identificationModule.nctId: "NCT04242238"
protocolSection.identificationModule.officialTitle: "A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.